GPT and metabolic dysfunction-associated steatotic liver disease: Another PPAR agonist used in studies that included patients with NAFLD is saroglitazar, alongside the improvement of alanine aminotransferase (ALT) and dyslipidemia, showed a decreased liver fat content of up to 45% after 16 weeks [58].